ate showed a proliferation of blasts which were positive for myeloperoxidase and fluoride-inhibitable nonspecific esterase. AML (FAB classification M4) was diagnosed. She was (100 mg/m 2 i.v. for 5 consecutive days). During hematopoietic recovery after the second course of consolidation ther-CMV infection must be considered in the differential diagnosis in cases of unexplained fever or pneumonia apy, PBMC were harvested by continuous flow leukapheresis and cryopreserved. The total number of PBMC following APBSCT.
drome. Finally, CMV interstitial pneumonia developed and death ensued. Even after APBSCT, there can be a i.v. for 3 consecutive days), while the second comprised intermediate-dose Ara-C combined with etoposide short period of immune deficiency resembling that occurring following allogeneic or autologous BMT.
(100 mg/m 2 i.v. for 5 consecutive days). During hematopoietic recovery after the second course of consolidation ther-CMV infection must be considered in the differential diagnosis in cases of unexplained fever or pneumonia apy, PBMC were harvested by continuous flow leukapheresis and cryopreserved. The total number of PBMC following APBSCT. Keywords: cytomegalovirus; interstitial pneumonia; pericollected was 1.1 × 10 1 Compared to BMT, APBSCT results in BEA) consisted of rhG-CSF (Kirin, Tokyo, Japan) adminisrapid hematopoietic recovery which reduces the morbidity tered at a dose of 5 g/kg i.v. daily on days −14 to −8, and mortality from bacterial and/or fungal infectious com-10 g/kg on days −7 and −6, and 20 g/kg on days −5 and plications. 2 However, reports about viral infections follow-−4, Ara-C 100 mg/m 2 by continuous i.v. over 24 h daily on ing APBSCT are very few. Recently, Sakuma et al 3 days −12 to −6, busulfan 4 mg/kg p.o. in divided doses reported that there were no cases of cytomegalovirus daily on day −9 to −6, etoposide 20 mg/kg i.v. daily on (CMV)-associated disease among their 105 patients who days −5 and −4, and Ara-C 3 g/m 2 twice daily i.v. on days had received APBSCT. We report the case of a Japanese −3 and −2. 4 Acyclovir was administered at a dose of woman who received APBSCT and subsequently 5 mg/kg i.v. daily on days +1 to +14, and anti-CMV hyperdeveloped fatal CMV interstitial pneumonia (IP).
immune globulin 100 mg/kg on days +1 and +2. On day +6 fever developed which did not resolve. Nevertheless, her granulocyte count exceeded 0.5 × 10 9 /l on day +11. Bone Case report marrow aspiration on day +25 showed marked hemophagocytosis. Hemophagocytic syndrome was diagnosed and A 52-year-old Japanese woman was referred to our hospital prednisolone 1 mg/kg i.v. daily was administered. She because of a syncopal attack in May 1996. Her hemoglobin became afebrile temporarily, but then fever recurred. On was 89 g/l, white blood cell count 177. /l, and platelet count 6 × 10 9 /l on day +48). On day +56, hemorrhagic cystitis developed and CMV was isolated This is our first case of fatal CMV-associated disease following APBSCT, our hospitals having undertaken 67 from the urine. Again, the CMV antigenemia assay revealed strong positivity (16/5 × 10 4 WBC), and foscarnet cases of APBSCT for AML from 1989 to 1996. Sakuma et al 3 reported that none of 17 pediatric APBSCT patients (60 mg/kg three times daily i.v.) was administered. 6 With foscarnet treatment, CMV-antigenemia disappeared, and were positive for CMV antigenemia at day +35, although four of them were CMV-seronegative prior to APBSCT. administration of foscarnet was terminated on day +84. Due to recurrence of CMV-associated hemophagocytic synIn contrast, Boeckh et al 8 reported that among 41 CMVseropositive APBSCT patients, 15 were CMV-antigenemia drome (day +112 CMV-antigenemia 2/5 × 10 4 WBC), granulocytopenia developed and foscarnet was re-administered positive at day +16 to +61, and one patient developed CMV retinitis on day +130. There were differences in patient ages on day +116. With this treatment, the granulocytopenia and CMV antigenemia resolved. The administration of foscarand CMV seropositivity: most patients of Sakuma et al were pediatric, and of Boeckh et al were adult. Peusser et net was again terminated on day +140. On day +158, IP developed ( Figure 1 ) and progressive respiratory failure al 9 reported that positive pre-transplant CMV serology was the most significant risk factor for CMV infection in the occurred. Bronchoalveolar lavage revealed inclusion bodies and CMV IP was diagnosed. Despite treatment with foscarsetting of ABMT. The higher incidence of CMV antigenemia and CMV-associated disease in the series of Boeckh net and anti-CMV hyperimmune globulin, she died of respiratory failure on day +171 (Figure 2) .
et al compared to that of Sakuma et al seems to be influenced by older ages and higher CMV seropositivity. Even after APBSCT, there can be a short period of immune deficiency resembling that occurring after allogeneic or Discussion autologous BMT. 10 Moreover, fatal CMV-associated disease has been reported following ABMT.
8
APBSCT has been used increasingly because it results in rapid hematopoietic recovery and allows rapid immune
We consider that the possibility of serious CMV-associated disease developing after APBSCT should not be disreconstitution. Compared to allogeneic BMT, serious infectious complications are much less likely to develop after counted. We cannot elucidate the reason why our patient suffered from refractory CMV-associated disease, although APBSCT. CMV-associated disease is a serious complication following allogeneic stem cell transplantation.
5,7 On prednisolone administered for the treatment of hemophago- be considered in the differential diagnosis in cases of unex-
